1T-LSD: Difference between revisions
Content deleted Content added
No edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
| routes_of_administration = [[Oral administration|By mouth]], [[Sublingual administration|under the tongue]] <!--Identifiers--> |
| routes_of_administration = [[Oral administration|By mouth]], [[Sublingual administration|under the tongue]] <!--Identifiers--> |
||
| CAS_number = |
| CAS_number = |
||
| PubChem = |
| PubChem = 170763788 |
||
| UNII = |
| UNII = |
||
| ChemSpiderID = |
| ChemSpiderID = |
||
Revision as of 22:03, 8 May 2024
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth, under the tongue |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C25H27N3O2S |
| Molar mass | 433.57 g·mol−1 |
| 3D model (JSmol) | |
| |
1T-LSD (N1-(thiophene-2-carbonyl)-lysergic acid diethylamide, SYN-L-021) is an acylated derivative of lysergic acid diethylamide (LSD), which has been sold as a designer drug. It was first identified in Japan in 2023 on blotter paper misrepresented as containing 1D-LSD, but which on analysis was determined to contain 1T-LSD instead.[1]
See also
References
 | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |